NCT07732322

Brief Summary

Vaginal natural opening transendoscopic surgery (vNOTES) has emerged as a minimally invasive surgical approach in gynecological procedures. By utilizing the vaginal passage as a natural opening, vNOTES eliminates abdominal incisions and has been associated with less postoperative pain, shorter hospital stays, and faster recovery compared to traditional laparoscopic surgery. Despite these advantages, patients undergoing vNOTES may still experience significant perioperative pain due to visceral pelvic manipulation, colpotomy, and uterine traction during the procedure. Recently, sacral modification of ESP block has been described as a promising technique for surgeries involving sacral and perineal regions. Ultrasound-guided sacral ESP block has demonstrated beneficial postoperative analgesic effects in procedures such as pilonidal sinus surgery and other perineal operations. However, the potential role of sacral ESP block in gynecological procedures, particularly in vNOTES surgery, has not yet been sufficiently explored. Pelvic organs receive complex autonomic and somatic innervation, primarily originating from the sacral segments (S2-S4), including the pelvic splanchnic nerves and the pudendal nerve. Targeting these nerve pathways with sacral ESP block can provide effective analgesia for both the visceral and somatic components of pain associated with vNOTES procedures. Therefore, this prospective randomized study aimed to evaluate the effect of ultrasound-guided sacral erector spinae plane block on intraoperative opioid consumption in patients undergoing vNOTES surgery. It was hypothesized that adding sacral ESP block to general anesthesia would reduce intraoperative remifentanil requirements, lower postoperative pain scores, and decrease the amount of analgesics consumed postoperatively. The primary objective of this study was to investigate the effects of sacral ESP block on intraoperative opioid consumption in challenging vNOTES; the secondary objective was to determine its effects on postoperative pain scores and the amount of analgesics consumed.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
1mo left

Started Jul 2026

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress25%
Jul 2026Aug 2026

First Submitted

Initial submission to the registry

July 24, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

July 25, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 28, 2026

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 10, 2026

Expected
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 25, 2026

Last Updated

July 29, 2026

Status Verified

July 1, 2026

Enrollment Period

16 days

First QC Date

July 24, 2026

Last Update Submit

July 28, 2026

Conditions

Keywords

vNOTESSacral erector spinae plane blockPeripheral nerve blockGynecological oncological surgeryAnesthesia

Outcome Measures

Primary Outcomes (1)

  • intraoperative remifentanil compsumtion

    intraoperative period

Study Arms (2)

General anesthesia

ACTIVE COMPARATOR

Intraoperative remifentanil consumption will be recorded after standard general anesthesia induction. If heart rate and mean arterial pressure change by more than 20% from baseline, the remifentanil dose will be increased or decreased by 0.02-0.03 mcg/kg/min (Stepwise remifentanil titration protocol). Heart rate and mean arterial pressure values will be recorded during colpotomy and uterine traction. All patients will receive a standard analgesia protocol: 1 gram of paracetamol every 8 hours, 1 mg/kg of diclofenac every 12 hours, and 50 mg of tramadol as rescue analgesia if VAS \> 4. The total tramadol dose consumed will be recorded. Postoperative NRS scores at 0, 2, 6, 12, and 24 hours will be recorded (0: No pain, 10: Unbearable pain). Postoperative nausea, vomiting, and adverse events will also be recorded.

Procedure: Sacral ESP block

General anesthesia + Sacral ESP block

ACTIVE COMPARATOR

Bilateral S2 level sacral ESP block will be performed under ultrasound guidance. A total of 20 ml of block solution will be administered to one side, consisting of 10 ml of 0.5% bupivacaine, 5 ml of 2% lidocaine, and 5 ml of saline. Intraoperative remifentanil consumption will be recorded after standard general anesthesia induction. If heart rate and mean arterial pressure change by more than 20% from baseline, the remifentanil dose will be increased or decreased by 0.02-0.03 mcg/kg/min (Stepwise remifentanil titration protocol). Heart rate and mean arterial pressure values will be recorded during colpotomy and uterine traction. All patients will receive a standard analgesia protocol: 1 gram of paracetamol every 8 hours, 1 mg/kg of diclofenac every 12 hours, and 50 mg of tramadol as rescue analgesia if VAS \> 4. The total tramadol dose consumed will be recorded. Postoperative NRS scores will be recorded at 0, 2, 6, 12, and 24 hours (0: No pain, 10: Unbearable pain). Postoperative nau

Procedure: Sacral ESP block

Interventions

Patients scheduled for vNOTES surgery will be divided into two groups: general anesthesia and general anesthesia + sacral ESP block. Intraoperative opioid consumption and other parameters of the patients will be recorded.

General anesthesiaGeneral anesthesia + Sacral ESP block

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailswomen undergoing elective vNOTES surgery
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ages 18-65
  • Planned for elective vNOTES surgery
  • ASA 1-3
  • BMI \<35

You may not qualify if:

  • ASA 4
  • Planned emergency surgery
  • Pregnant patients
  • Persons with coagulopathy
  • Persons with allergy to local anesthetics
  • Persons with neurological disease
  • Persons with infection in the area where the block will be performed
  • Persons who refuse to participate in the study for any reason

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Specialist

Study Record Dates

First Submitted

July 24, 2026

First Posted

July 28, 2026

Study Start

July 25, 2026

Primary Completion (Estimated)

August 10, 2026

Study Completion (Estimated)

August 25, 2026

Last Updated

July 29, 2026

Record last verified: 2026-07